^
    Back
    Association details:
    Biomarker:PLK4 expression
    Cancer:Leiomyosarcoma
    Drug:ocifisertib (CFI-400945) (PLK4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    Improvement of drug efficacy of polo-like kinase 4 inhibitor in the treatment of uterine leiomyosarcoma.

    Published date:
    05/15/2020
    Excerpt:
    Ut-LMS cell lines expressed high levels of PLK4 and were highly sensitive (IC50 in nM range) to CFI-400945.